J
James F. Fries
Researcher at Stanford University
Publications - Â 369
Citations - Â 87747
James F. Fries is an academic researcher from Stanford University. The author has contributed to research in topics: Rheumatoid arthritis & Arthritis. The author has an hindex of 100, co-authored 369 publications receiving 83589 citations. Previous affiliations of James F. Fries include University of Saskatchewan & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Health risk changes with a low-cost individualized health promotion program: effects at up to 30 months.
TL;DR: A large and relatively long experience with a low-cost intervention delivered through the mail and using sequential time-oriented risk appraisal and personalized recommendations, each six months, together with self-management materials shows positive effects which continue to improve with time in program.
Journal ArticleDOI
A modular self-describing clinical databank system.
TL;DR: By increasing the information available to practicing physicians, medical speciality databanks may reinforce clinical practice sufficiently to allow modular expansion into a hospital network.
Journal Article
ARAMIS (the American Rheumatism Association Medical Information System). A prototypical national chronic-disease data bank.
James F. Fries,Dennis J. McShane +1 more
TL;DR: ARAMIS is a prototype of a national chronic-disease data-bank system consisting of parallel, longitudinal, clinical data sets from 17 diverse locations; the data describe the courses of thousands of patients with rheumatic disease followed over many years.
Journal Article
Predisposing factors in polymyositis-dermatomyositis: results of a nationwide survey.
TL;DR: It appears that vaccinations, toxic exposures and symptoms of allergic phenomena, throat infection, and upper respiratory infection are either neutral or are negatively associated with risk of PM-DM, findings which also raise important new etiologic questions, or perhaps lay old ones to rest.
Journal Article
Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis.
James F. Fries,Bonnie Bruce +1 more
TL;DR: OTC use of ASA, IBU, or APAP carries little risk of serious GI toxicity for most persons, although RA patients tended to have higher rates than OA patients and most serious problems encountered were in higher-risk patients.